Articles tagged with Cell Mediated Immunity
Researchers discover enzyme ANKIB1 crucial for innate immune signalling, driving type I and type III interferon induction. This finding solves a long-standing puzzle in innate immunity and provides opportunities for new therapies for devastating diseases.
Researchers will investigate the role of interleukin-1 receptor type 1 (IL-1R1) in brain function, behavior, and psychiatric health. The study aims to define the physiological role of IL-1R1 in the brain and explore its influence on social behaviors.
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
Three young scientists received top honors at the 2025 Blavatnik National Awards for Young Scientists, each receiving a $250,000 prize for their innovative work on critical global issues. The awards recognize exceptional scientific achievement and innovation by U.S.-based researchers under 42 years old.
Researchers at CU Anschutz discovered a genetic program within lymphatic endothelial cells that enables storage and archival of antigens, helping the immune system remember infections. This understanding could lead to improved vaccines and therapies by fine-tuning immune memory.
Researchers found that immature neutrophils migrate into inflamed tissues upon stimulation by interferon-γ, suppressing inflammation and reducing tissue damage. In humans, these cells also produce interleukin-10, which increases in the blood of COVID-19 patients.
Researchers have identified specialized immune cells in the intestine that produce chemical messengers triggering anaphylaxis. Targeting these chemicals, like zileuton, may offer a new approach to preventing food-triggered anaphylaxis.
Researchers at the University of Chicago discovered that random fluctuations in gene expression enable certain cells to express genes from other tissues, promoting immune system training and tissue repair. This 'epigenetic noise' can also contribute to cancer development by allowing cancer cells to access a broader range of genes.
Researchers discover mitochondrial transfer between cancer cells and immune cells as a key immune evasion strategy. Cancer cells can reshape the tumor microenvironment to weaken tumor-infiltrating lymphocytes, and mitochondria play a significant role in this process.
Patients with 18q deletion syndrome exhibit both cellular and humoral immunodeficiency, characterized by low immunoglobulin levels and impaired T-cell function. Regular testing for both cellular and humoral immunity can allow for early detection of combined immune deficiencies and improve clinical outcomes.
A recent study reveals that NK cells can memorize viral antigens and differentiate into immune memory NK cells with considerable killing ability. Themis2, a cytoplasmic protein, plays a crucial role in regulating this process.
Researchers from Nara Institute of Science and Technology found that alveolar macrophages act as antigen-presenting cells to prime CD8+ T cell expansion in the lungs. This process involves the production of interleukin 18, leading to the development of resident memory-type cell populations.
Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.
A recent international study has shed light on the inner workings of the adaptive immune response, revealing how killer T cells recognize viral invaders using molecular road signs. The study highlights the crucial role of chaperones in ensuring the stability and longevity of these road signs, allowing for more effective detection and d...
Researchers at Hokkaido University and Texas A¼M University identified a key mechanism used by SARS-CoV-2 to evade host immune systems, targeting the MHC class I pathway. The study found that the virus suppresses the activation of this pathway using the ORF6 protein, allowing it to persist in the body and infect others.
A new research strategy enhances COVID-19 vaccine effectiveness by providing 'border protection' immunity in the nose, mouth and blood. The approach involves suppressing an enzyme that breaks down both pathogens and immune cells, resulting in a robust antibody response and improved protection against infections.
Researchers found a promising adjuvant, chitosan, induces immune response through a DNA-sensing pathway in cells. This discovery provides a roadmap for developing vaccines that trigger 'cell-mediated immunity',